Suppr超能文献

miR-34a与塞来昔布在骨肉瘤中的潜在联合效应。

The potential combinational effect of miR-34a with celecoxib in osteosarcoma.

作者信息

Chen Xia, Peng Dan, Shen Yi, Liu Bo, Zhou Hongkang, Tao Huai, Huang Jufang

机构信息

aDepartment of Orthopedics, The Second Xiangya Hospital of Central South University bDepartment of Anatomy and Neurobiology, School of Basic Medical Science, Central South University cDepartment of Biochemistry and Molecular Biology dDivision of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, Hunan, China.

出版信息

Anticancer Drugs. 2017 Sep;28(8):888-897. doi: 10.1097/CAD.0000000000000530.

Abstract

Advanced osteosarcoma (OS) is usually treated by preoperative and postoperative chemotherapy, but there are a very limited number of active agents. Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro. However, the potential combinational effect of Cel with other biological therapy has not been reported in OS cells. In this study, the effects of Cel, miR-34a mimics, and their combination on cell proliferation (MTT assay), migration (in-vitro scratch assay), invasion (transwell assay), mRNA (real-time PCR), and protein (Western blot) expression of associated signal transductions were investigated in cultured MG63 cells. The results showed that miR-34a mimics transfection and Cel treatment significantly decreased cell viability, migration, and invasion in MG63 cells, with their combination being more effective. In contrast, miR-34a inhibitors transfection exerted an effect opposite to miR-34a mimics on cell viability, migration, and invasion. The antitumoral effects of miR-34a, Cel, and their combination were observed in significant up-regulated expression of PTEN and GSK-3β, down-regulated expression of ROCK1, Notch1, and MMP9 as well as Akt Ser phosphorylation. Our data suggested that miR-34a exerts a combinational effect with Cel on the cell proliferation, migration, and invasion in OS cells through regulating Notch1/ROCK1-PTEN-Akt-GSK-3β signaling and MMP9 gene expression.

摘要

晚期骨肉瘤(OS)通常采用术前和术后化疗进行治疗,但有效的药物数量非常有限。塞来昔布(Cel)是一种COX-2选择性非甾体抗炎药,其抗肿瘤作用已在包括OS细胞在内的多种癌症的体外实验中得到广泛证实。然而,Cel与其他生物疗法的潜在联合作用在OS细胞中尚未见报道。在本研究中,我们在培养的MG63细胞中研究了Cel、miR-34a模拟物及其联合使用对细胞增殖(MTT法)、迁移(体外划痕试验)、侵袭(Transwell试验)、相关信号转导的mRNA(实时PCR)和蛋白质(蛋白质印迹法)表达的影响。结果表明,miR-34a模拟物转染和Cel处理显著降低了MG63细胞的活力、迁移和侵袭能力,两者联合使用效果更佳。相反,miR-34a抑制剂转染对细胞活力、迁移和侵袭的影响与miR-34a模拟物相反。观察到miR-34a、Cel及其联合使用的抗肿瘤作用表现为PTEN和GSK-3β表达显著上调,ROCK1、Notch1和MMP9表达下调以及Akt丝氨酸磷酸化。我们的数据表明,miR-34a通过调节Notch1/ROCK1-PTEN-Akt-GSK-3β信号通路和MMP9基因表达,与Cel对OS细胞的增殖、迁移和侵袭发挥联合作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验